Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE:ZTS) is set to participate in the Cowen 41st Annual Health Care Conference on March 1, 2021. CEO Kristin Peck will present at 1:20 p.m. ET and answer questions from analysts. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations, with a replay available afterwards. As a leader in animal health, Zoetis generated $6.7 billion in revenue in 2020 and operates in over 100 countries, providing medicines, vaccines, and diagnostics for animal care.

Zoetis (NYSE:ZTS) will join the Bank of America Securities 2021 Animal Health Summit Virtual Forum on February 25, 2021. Glenn David, Executive Vice President and CFO, will present at 7:50 a.m. ET. Investors can listen to the live audio webcast at investor.zoetis.com/events-presentations, with a replay available post-event. Zoetis, a leader in animal health, reported $6.7 billion in annual revenue for 2020 and has a team of approximately 11,300 employees, providing essential products across over 100 countries.

Zoetis (NYSE:ZTS) has received marketing authorization from the European Commission for Solensia (frunevetmab), a groundbreaking treatment for feline osteoarthritis (OA). Affecting approximately 40% of cats, OA can severely impact their quality of life. Solensia is a monoclonal antibody that targets Nerve Growth Factor (NGF) to alleviate OA pain and is administered monthly by veterinarians. Clinical studies reveal that 76% of cat owners reported sustained improvements in their pets' pain symptoms, enhancing overall activity and sociability.

Zoetis Inc. (ZTS) reported Q4 2020 revenue of $1.8 billion, up 8% YoY, with net income of $359 million ($0.75/share). Adjusted net income was $438 million, relatively unchanged. Full-year revenue reached $6.7 billion, a 7% increase, with net income of $1.6 billion ($3.42/share). The company anticipates 2021 revenue growth of 9% to 11%, driven by strong performance in petcare and international markets. Key product approvals include Librela and Solensia for pain management in pets. Overall, Zoetis demonstrated resilience amidst COVID-19 challenges.

Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 16, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. CEO Kristin Peck and CFO Glenn David will present the information and answer questions from analysts. A live webcast will be accessible on the Zoetis investor website, and a replay will be available following the call. The company is a leader in animal health, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.

Zoetis (NYSE:ZTS) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Kristin Peck is scheduled to present at 10:00 a.m. ET and answer analysts' questions. Investors can access a live audio webcast of the presentation via investor.zoetis.com. A replay will be available post-event. Zoetis is a leader in animal health, with over 65 years of experience, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.

Zoetis Inc (NYSE:ZTS) has announced a 25% increase in its quarterly dividend, raising it to $0.25 per share for the first quarter of 2021. This increase reflects the company's strength and resilience in the animal health sector. The dividend will be paid on March 1, 2021, to shareholders on record as of January 20, 2021. Executive Vice President and CFO Glenn David noted the company's confidence in generating cash for future investments and their commitment to returning excess capital to shareholders.

Zoetis Inc (NYSE:ZTS) has appointed Antoinette Leatherberry to its Board of Directors, expanding the Board from 12 to 13 members. Leatherberry, a former Deloitte executive with 30 years of experience, will contribute to the Audit and Corporate Governance Committees. Her expertise in tech-enabled strategies aligns with Zoetis' goal of enhancing digital transformation in the animal health sector. Leatherberry has a strong track record in promoting diversity and holds significant educational qualifications, including a Mechanical Engineering degree and an MBA.